Halozyme Therapeutics, Inc. (HALO) dividends
HALO on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Halozyme Therapeutics, Inc. dividend: key facts
Own Halozyme Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next HALO dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Morgan Stanley downgrades Halozyme to Equal Weight on valuation11 Nov 2026 · TheFly
As previously reported, Morgan Stanley downgraded Halozyme (HALO) to Equal Weight from Overweight with a price target of $109, up from $105, citing valuation. Halozyme remains âone of the highest-qual...
- Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley11 Nov 2026 · TheFly
Morgan Stanley analyst Sean Laaman downgraded Halozyme (HALO) to Equal Weight from Overweight with a price target of $109, up from $105.
- Halozyme share selloff an attractive buying opportunity, says H.C. Wainwright7 Nov 2026 · TheFly
H.C. Wainwright tells investors in a research note that Halozymeâs (HALO) reaffirmed minimal CMS royalty exposure, strong royalty growth, and track record of earnings beats support confidence in anoth...
- Leerink downgraded Halozyme to Market Perform on limited upside potential6 Nov 2026 · TheFly
As previously reported, Leerink downgraded Halozyme (HALO) to Market Perform from Outperform with a price target of $117, up from $110, driven by financial model revisions, changing the discount rateâ¦
- Halozyme sees âzero to minimalâ royalty revenue impact to 2035 from CMS rule6 Nov 2026 · TheFly
Halozyme (HALO) Therapeutics confirmed that the company expects âzero to minimal royalty revenue impactâ based on its analysis of the final rule for the Medicare Drug Price Negotiation Program issuedâ¦
- Halozyme says Enhanze technology in J&Jâs Rybrevant Faspro6 Nov 2026 · TheFly
Halozyme (HALO) announced that Johnson & Johnson (JNJ) was granted accelerated approval from the Food and Drug Administration for Rybrevant Faspro, which is co-formulated with Enhanze, as a single age...
- Halozyme reports Q3 non-GAAP EPS $2.39, consensus $2.366 Nov 2026 · TheFly
Reports Q3 revenue $493M, consensus $493. âHalozyme (HALO) delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels,â sa...
- Halozyme reports Q3 non-GAAP EPS $2.39, consensus $2.366 Nov 2026 · TheFly
Reports Q3 revenue $493M, consensus $493. âHalozyme (HALO) delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels,â sa...
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.